England MenB vaccine for Year 13 and first-year students

According to the Department of Health and Social Care, thousands of young people across England will be offered protection against meningococcal B disease, usually shortened to MenB, before the 2026 academic year begins. If you are finishing Year 13 this summer, or you are under 25 and moving into university or residential further education for the first time in autumn 2026, this is an announcement worth paying close attention to. The first thing to understand is that this is a two-dose course, not a one-off jab. Officials say the first dose will be offered from the end of July 2026, with the second dose given in August, so students can build protection before the new term starts.

MenB is rare, but it is also extremely serious. UKHSA says meningococcal disease can be life-threatening, is fatal in around 10% of cases, and can leave survivors with long-term harm including amputations, hearing loss and brain damage. That is why this story matters even to readers who have never heard of MenB before. The infection can spread through close contact with someone carrying the bacteria. In plain terms, that can mean kissing, sharing drinks or vapes, or spending long periods in the same living space. For many families, that makes the risk easier to picture: it is not just about lecture halls, but about halls of residence, shared kitchens and the intense social contact that often comes with starting somewhere new.

This one-off programme follows a worrying run of cases. Earlier in 2026, the MenB outbreak in Kent became, in the government’s description, the fastest-growing and largest ever seen in the UK. Ministers say that outbreak response has now ended, but they also say there have been more clusters than normal this year, and some have been larger than expected. UKHSA data helps explain the concern. The agency recorded 313 confirmed MenB cases in England during 2024/25, representing about 83% of all invasive meningococcal disease cases. It says the disease affects babies, teenagers and young adults disproportionately. Babies are already offered MenB vaccination through the routine NHS schedule, which is why this new offer is focused on older students.

The eligibility rules are quite precise, so it is worth slowing down here. The programme covers everyone completing Year 13 in summer 2026 who was born between 1 September 2007 and 31 August 2008. That offer applies whether you are planning to go to university or not. It also covers people under 25 who are starting university for the first time in autumn 2026, as well as those moving into some residential further education settings for the first time. It does not cover postgraduates, or students going into a second year or later. International students under 25 who are entering their first year are being advised to get their first dose in their home country where possible.

The NHS says eligible Year 13 pupils will be contacted directly through the NHS App, text, email or letter, depending on the records it holds. NHS England expects appointments to be available through community pharmacies from the end of July, and says bookings should open in mid-July. **What this means for you:** if you are eligible, the key job is to make sure both appointments happen. Deputy Chief Medical Officer Dr Thomas Waite says the two doses need to be given at least four weeks apart for maximum protection. Under-25s starting university for the first time will also be able to book directly with participating pharmacies.

There is a clear reason for the summer timetable. UKHSA says cases of invasive meningococcal disease in this age group usually peak between October and November. That means protection needs to be in place before students settle into shared accommodation and the busiest part of first term begins. UKHSA also says the relative risk of invasive MenB disease is substantially higher in first-year university students than in their same-age peers. That does not mean every fresher is likely to become ill, but it does explain why health officials are concentrating on the point when young people first move into close, prolonged contact with lots of new people.

The government is calling this a one-off programme while it looks at whether a wider response may be needed. The Joint Committee on Vaccination and Immunisation, or JCVI, has already advised ministers on which groups should be prioritised for a targeted scheme after the recent outbreaks. Further advice on any longer-term programme is still expected. There is also existing evidence on the vaccine itself. The MenB vaccine already has an established safety record through the NHS childhood vaccination programme, and the Department of Health and Social Care says evidence from that infant programme shows around a 75% reduction in MenB disease among eligible vaccinated groups. That does not answer every future policy question, but it does help explain why officials are confident about using the vaccine now.

Charities and campaigners have welcomed the move while also saying the conversation is not over. Meningitis Research Foundation said rapid action matters because outbreaks, although uncommon, can be devastating. Meningitis Now described the announcement as a major step, while arguing that there is still more work to do for groups not covered by this one-off offer, including younger teenagers and students who are already at university. Universities, colleges, NHS bodies and student groups are also being asked to help spread consistent messages about the rollout. For students, parents and carers, the takeaway is simple. If you are in the eligible group, look out for the invitation, book early and do not stop after the first dose. This programme will not change the seriousness of MenB, but it should give many young people a stronger layer of protection before a major life change, and that matters.